DUB-le Trouble for Cell Survival.
Expression of MCL-1 is frequently elevated in cancer and is implicated in the resistance to chemotherapy by the BCL-2 small molecule inhibitor ABT-737. A recent paper in Nature identified USP9X as an antagonist of MCL-1 ubiquitinylation and degradation. Often upregulated in tumor cells, USP9X activity influences the response to ABT-737.